# Alfresa Holdings

> Alfresa Holdings is a VC fund in Tokyo backing Health Care and Medical. See 11 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Tokyo, Japan
- Total investments: 11
- Last investment: Jun 2026
- Lead investor: 64%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/alfresa-corporation
- Website: https://www.alfresa.com/

Alfresa Holdings is a VC fund in Tokyo focused on Health Care and Medical. Alfresa Holdings engages in the management of its subsidiaries that deal with wholesaling, manufacturing, import, and export of pharmaceutical products, diagnostic reagents, and medical devices. It operates through the following segments: Ethical Pharmaceuticals Wholesaling, Self-Medication Products Wholesaling, and Manufacturing. The EthicalPharmaceuticals Wholesaling segment provides wholesale prescription drugs, medical diagnostic reagents, and medical devices, equipment, and materials to hospitals, clinics, dispensing pharmacies, and other institutions. The Self-Medication Products Wholesaling segment sells general over-the-counter drugs. The Manufacturing segment manufactures and markets products in the fields of pharmaceuticals, diagnostic reagents, and medical devices. The company was founded on September 29, 2003, and is headquartered in Tokyo, Japan.

## Contacts

5 contacts available for Alfresa Holdings. Shizune tracks 4 team members at Alfresa Holdings. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/alfresa-holdings?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 9 | 82% |
| Medical | 4 | 36% |
| Manufacturing | 4 | 36% |
| Biotechnology | 3 | 27% |
| Pharmaceutical | 3 | 27% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Corporate Round | 5 | 45% |
| Series B | 2 | 18% |
| Series A | 1 | 9% |
| Series C | 1 | 9% |
| Series D | 1 | 9% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Japan | 10 | 91% |
| Austria | 1 | 9% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Koichi Masunaga | Director, Deputy President | 0 | https://shizune.co/investors/profile/koichi-masunaga |
| Ryuji Arakawa | Director, Vice President & CEO | 0 | https://shizune.co/investors/profile/ryuji-arakawa |
| Taizo Kubo | Representative Director & President | 0 | https://shizune.co/investors/profile/taizo-kubo |
| Yasuki Izumi | Director, Deputy President | 0 | https://shizune.co/investors/profile/yasuki-izumi |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| eMind | eMind is a consulting firm that provides planning, design, and management of information systems for businesses and medical institutions. | $2.2M | Corporate Round | Jun 23, 2026 |  |
| Alfenax Biologics | Alfenax Biologics is a Japanese joint venture established by Mycenax Biotech, Alfresa Holdings, Kidswell Bio Corporation, and Chiome Bioscience to build a dedicated biologics manufacturing base in Japan. |  | Corporate Round | Mar 09, 2026 |  |
| Innovacell | Innovacell is a biotechnology firm entirely focused on the area of tissue engineering and it operates one of Europe's largest and most modern production facilities for the proliferation of the body's own tissue cells. Its supervisory board is chaired by the experienced financial expert, Dr. Harald Pöttinger, a director of Alpine EquityManagement AG, based in Bregenz, Austria. Innovacell currently employs 20 staff as well as numerous outside experts. |  | Series D | Aug 21, 2025 |  |
| HekaBio | HekaBio is a healthcare development, investment, and commercialization platform with experience in oncology, radiation, and cardiovascular therapies. They invest in innovations in oncology, radiation, and cardiovascular therapy and commercialization. HekaBio enables patients by accelerating access to global healthcare innovations. |  | Corporate Round | Jun 16, 2025 |  |
| Gexval | GEXVal is to help patients and families fighting against orphan and intractable diseases | $1.9M | Series C | Jan 16, 2025 |  |
| Medcom | Frontier Field is a venture company that brings the medical and healthcare fields together with the power of IT. It also engaged in the planning, development, sales, and maintenance of the nibyo mobile smartphone exclusively for medical institutions. | $7.4M | Series B | Jun 08, 2022 |  |
| Donut Robotics | Donut Robotics develops robots with digital intelligence to solve social problems. The company's products include clip Ear, C-Face, and Cinnamon. Clip Ear is a smart earphone while C-Face is a smart facemask that works with smartphones and lastly Cinnamon, a smart robot that functions as a receptionist in airports, public facilities, andcorporate receptions. |  | Venture - Series Unknown | May 14, 2021 |  |
| Metcela | Metcela is a clinical-stage biotech startup providing patients with an innovative and alternative treatment option for heart disease. The company's lead asset, MTC001 is a cell therapy based on VCAM-1-positive Cardiac Fibroblast (VCF) that re-established a favorable microenvironment and repaired damaged heart tissues in preclinical studies.Metcela's therapy uses a specific fibroblast cell that is obtained from the patient's heart and instead of replacing them, it repairs the damage by enhancing the cells' ability to heal, providing patients with an effective and reasonably-priced cure for heart failure.It was founded on March 9, 2016, and is headquartered in Kawasaki, Japan. | $12.7M | Series B | Jan 04, 2021 |  |
| PharmaBio | PharmaBio is a health care company that manufacturing and development company specializing in products such as regenerative medicine, we support GCTP-compliant manufacturing with low risk and cost burden, and provide various services and products that enhance safety and quality. |  | Corporate Round | Jun 17, 2020 |  |
| Human Life CORD | HLC is a Japan-originated cell therapy company building a first-in-class global ecosystem for UC-MSC–based products. By transforming umbilical cord tissue into a scalable medical resource, we enable reliable, high-quality cell therapy manufacturing at global scale. | $10.1M | Series A | Apr 03, 2020 |  |

10 of 11 investments shown.

## Co-investors
- [UTEC - The University of Tokyo Edge Capital Partners](https://shizune.co/investors/profile/utec) — VC Fund, 3 deals together
- [Arcus Investment](https://shizune.co/investors/profile/arcus-investment) — VC Fund, 1 deal together
- [Aska Pharmaceutical](https://shizune.co/investors/profile/aska-pharmaceutical) — VC Fund, 1 deal together
- [Chiome Bioscience](https://shizune.co/investors/profile/chiome-bioscience) — VC Fund, 1 deal together
- [Dai-ichi Life](https://shizune.co/investors/profile/dai-ichi-life) — VC Fund, 1 deal together
- [DBJ Capital](https://shizune.co/investors/profile/dbj-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Info Edge](https://shizune.co/investors/profile/info-edge) — VC Fund
- [Vector](https://shizune.co/investors/profile/vector-inc-) — VC Fund
- [Akatsuki Games Inc.](https://shizune.co/investors/profile/akatsuki-3) — VC Fund

## FAQ

### What does Alfresa Holdings invest in?

Alfresa Holdings invests primarily in Health Care, Medical and Manufacturing startups, most often at Corporate Round and Series B stage. Most of the 11 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Alfresa Holdings?

Public channels for Alfresa Holdings include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Alfresa Holdings?

The team at Alfresa Holdings includes Koichi Masunaga (Director, Deputy President), Ryuji Arakawa (Director, Vice President & CEO) and Taizo Kubo (Representative Director & President). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co